NYSE American accepts VolitionRx compliance plan; shares continue trading until Aug 2027 review

VOLITIONRX LTD

Received non-compliance notice on Feb 6, 2026 for stockholders' equity deficiency (below $2M threshold).
Compliance plan submitted by March 8, 2026; accepted by NYSE American on April 22, 2026.
Company has until August 6, 2027 to regain compliance; subject to periodic NYSE American review.
If plan progress insufficient or compliance not met by deadline, delisting proceedings may be initiated.
No immediate impact on listing; common stock continues trading under symbol VNRX on NYSE American.

item 3.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.